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A B S T R A C T
Chronic inflammation is associated to 25% of cancer cases according to epidemiological data. Therefore, in-
hibition of inflammation-induced carcinogenesis can be an efficient therapeutic approach for cancer chemo-
prevention in drug development studies. It is also determined that anti-inflammatory drugs reduce cancer in-
cidence. Cell culture-based in vitro screening methods are used as a fast and efficient method to investigate the
biological activities of the biomolecules. In addition, saponins are molecules that are isolated from natural
sources and are known to have potential for tumor inhibition. Studies on the preparation of analogues of cy-
cloartane-type sapogenols (9,19-cyclolanostanes) have so far been limited. Therefore we have decided to direct
our efforts toward the exploration of new anti-tumor agents prepared from cycloastragenol and its production
artifact astragenol. The semi-synthetic derivatives were prepared mainly by oxidation, condensation, alkylation,
acylation, and elimination reactions. After preliminary studies, five sapogenol analogues, two of which were new
compounds (2 and 3), were selected and screened for their inhibitory activity on cell viability and NFκB sig-
naling pathway activity in LNCaP prostate cancer cells. We found that the astragenol derivatives 1 and 2 as well
as cycloastragenol derivatives 3, 4, and 5 exhibited strong inhibitory activity on NFκB signaling leading the
repression of NFκB transcriptional activation and suppressed cell proliferation. The results suggested that these
molecules might have significant potential for chemoprevention of prostate carcinogenesis induced by in-
flammatory NFκB signaling pathway.
1. Introduction
Experimental and clinical studies demonstrate that anti-in-
flammatory drugs reduce the incidence of various types of cancer, in
particular prostate, colon, and stomach [1]. In prostate cancer, regular
use of aspirin and NSAIDs was determined to decrease the cancer risk
about 15–20% in prospective and case control studies [2]. Most anti-
inflammatory agents show their anticancer effect through cellular me-
chanisms via inhibition of NFκB, COX2, and prostaglandin synthesis
[2–6].
Chronic inflammation alters the cellular levels of reactive oxygen
and nitrogen species (RONS), inflammatory cytokines, and other in-
flammatory mediators such as cyclooxygenase-2 (COX2), and also ac-
tivates proto-oncogenes in the meanwhile. However, cellular response
to inflammatory mechanisms can be pro- or anti-tumorigenic de-
pending on the balance between inflammatory mediators in a cell [2].
One of the most important mediators of inflammation is NFκB,
which is a transcription factor and the key molecule of pro-in-
flammatory signaling leading tumorigenesis. While some of NFκB
transcriptional targets activate the cell cycle, angiogenesis, and me-
tastasis, a group of targets inhibit apoptotic genes. Furthermore, many
gene products of NFκB targets can be counted as mediators of innate
https://doi.org/10.1016/j.steroids.2018.04.005
Received 13 September 2017; Received in revised form 2 April 2018; Accepted 12 April 2018
⁎ Corresponding authors at: Ege University, Faculty of Pharmacy, Department of Pharmaceutical Biotechnology, Izmir, Turkey (B. Debeleç-Bütüner); Ege University, Faculty of
Engineering, Department of Bioengineering, Izmir, Turkey (E. Bedir).
1 Present address: Division of Cancer Genetics and Therapeutics, Laboratory of NFκB Signaling, Institute of Molecular and Cell Biology (IMCB), A∗STAR (Agency for Science,
Technology and Research), Singapore 138673, Singapore.
2 Present address: Izmir Institute of Technology, Faculty of Engineering, Department of Bioengineering, Izmir, Turkey.
E-mail addresses: bilge.debelec@ege.edu.tr (B. Debeleç-Bütüner), erdalbedir@iyte.edu.tr (E. Bedir).
Steroids 135 (2018) 9–20
Available online 18 April 2018
0039-128X/ © 2018 Elsevier Inc. All rights reserved.
T
immune response and inflammation, such as cytokines, chemokines,
proteases including the NOS2, and COX2 [7,8]. Cytokines are key
molecules of inflammation and immune response. The balance between
pro- and anti-inflammatory cytokines determines the ultimate effect on
cellular mechanisms leading to tumor growth or the inhibition. How-
ever, uncontrolled and sustained productions of pro-inflammatory cy-
tokines result in tumorigenic alterations in cellular mechanisms func-
tioning in cell proliferation, differentiation and apoptosis. In addition,
pro-inflammatory NFκB pathway is activated by TNF-α, of which
moderate levels also lead to tumorigenesis [2,7].
Infection and chronic inflammation are determined to be a sig-
nificant cause of many cancer types [7,9–11]. Therefore, many chronic
inflammatory diseases result in increased cancer risk. Long-term use of
NSAIDs is found to be marginally correlated to decreased risk of breast,
colon, prostate, lung and stomach cancer cases [12–14]. Additionally,
in clinical studies investigating ROS level alterations and cancer risk
due to the regular use of antioxidants, daily use of 50mg vitamin E is
also determined to be effective on reduced prostate cancer incidence
(32%) and mortality (41%). Negative correlation between use of anti-
inflammatory drugs and cancer risk clearly shows the role of active
inflammation on stimulating carcinogenesis that might be possible to be
inhibited [2].
Natural products provide a wide source for drug development stu-
dies, and the strategy of synthesizing semi-synthetic derivatives of
secondary metabolites by chemical modifications leads to higher
structural diversity. Saponins are polar glycosylates, which consist of
triterpene/steroid aglycone with one or more sugar chains. They have a
wide range of biological activity such as hemolytic, antimicrobial, an-
tifungal, anti-inflammatory, antiviral, cytotoxic and antitumoral in lit-
erature [15,16]. Triterpenoids have a significant role in the regulation
of inflammation. Many triterpenic structures such as avicine, as-
tragalosides, betulin, betulinic acid, oleandrin, oleanolic acid and sai-
kosaponins show a suppressor effect on NFκB signaling pathway [17].
In addition, less studied cycloartane-type saponins with low molecular
weight are suggested as potential antitumor molecules since they are
bioregulators inhibiting NFκB pathway [18,19].
In this study, we aimed to prepare semi-synthetic analogs of cy-
cloastragenol and astragenol and to investigate the potential anti-in-
flammatory activity of the selected compounds (1–5) by bioactivity
studies including inhibition of NFκB signaling and cell proliferation on
LNCaP prostate cancer cells.
2. Experimental
2.1. Derivatization of cycloastragenol and astragenol
2.1.1. Cycloastragenol (CA)
(20R, 24S)-3β,6α,16β,25-tetrahydroxy-20,24-epoxy-9,19-cyclola-
nostane: CA (98% purity) was donated by Bionorm Natural Products
(Turkey) [20].
2.1.2. Astragenol (AG)
((20R, 24S)-3β,6α,16β,25-tetrahydroxy-20,24-epoxy-lanost-9(11)-
ene): AG was synthesized from 980mg (2.0 mmol) of cycloastragenol,
which was dissolved in MeOH (50mL), then treated with conc. H2SO4
(5mL). The whole mixture was heated under reflux for 6 h. The reac-
tion mixture was poured into water (250mL) and was extracted three
times with 250mL EtOAc. The EtOAc extracts were washed succes-
sively with sat. NaHCO3 aq. (250mL) then water (250mL), and dried
over Na2SO4 and filtered. The filtrates were evaporated and chroma-
tographic separation of the crude products on a silica gel column was
performed by using n-hexane:EtOAc (6:4) to give AG (63.9 mg lyophi-
lized white powder, 65.2% yield) [20].
2.1.3. Compound 1
(Astragenol-3,6-diacetate) ((20R,24S)-3β,6α,16β,25-tetrahydroxy-
20,24-epoxy-lanost-9(11)-ene-3,6-diacetate): To a solution of AG
(50mg, 0.102mmol) in pyridine (5mL) at 25 °C, acetic anhydride
(250 µL) was added. The reaction mixture was stirred at room tem-
perature for 12 h, quenched with water (50mL) and extracted three
times with 50mL EtOAc. The organic layers were dried over Na2SO4,
filtered and concentrated. The residue was then purified on a silica gel
column chromatography (n-hexane: EtOAc; 8:2) to produce 1 (6.62mg
lyophilized white-off powder, 11.4% yield) [20].
2.1.4. Compound 2
((20S,24S)-25-hydroxy-20,24-epoxy-lanost-9(11)-ene-3,6,16-
trione): To a stirring solution of AG (100mg, 0.02mmol) in acetone
(100mL), the Jones reagent (0.4 mL, 3.3 mmol) was added slowly at ice
bath, and stirred till completion of the reaction. After adding sat.
NaHCO3 aq. (100mL), the aqueous mixture was extracted three times
with 25mL dichloromethane. The combined organic layers were wa-
shed with brine solution, dried over Na2SO4, and filtered. The filtrate
was evaporated, and chromatographic separation of the crude product
on a silica gel column was performed by using n-hexanes:EtOAc (8:2) as
eluent to give 2a (74.7 mg lyophilized white powder, 74.7% yield)
[21]. 2a (3,6,16-trioxo-astragenol) (120mg) was dissolved in 8mL THF
and was added NaOMe (135mg) at room temperature. The reaction
mixture was stirred overnight, and sat. aq. NaHCO3 was added to the
solution. The aqueous mixture was extracted three times with 25mL
dichloromethane. The combined organic layers were washed with brine
solution, and dried over Na2SO4 and filtered. The filtrate was evapo-
rated, and the crude product was purified on a silica gel column
chromatography (n-hexane:EtOAc; 9:1) to give 2 (19.2 mg lyophilized
white-off powder, 19.2% yield).
2.1.5. Compound 3
(Cycloastragenol-3,6-dipropionate) ((20R,24S)-3β,6α,16β,25-tetra-
hydroxy-20,24-epoxy-9,19-cyclolanostane-3,6-dipropionate): 400 µL
propionic anhydride (3.12 mmol) was added dropwise to a solution of
CA (100mg, 0.203mmol) and 5mg DMAP (0.04mmol) in pyridine
(10.0 mL). The reaction mixture was heated under reflux for 12 h. The
solution of completed reaction mixture was added to the cold 1M HCl
solution (100mL), and it was extracted four times with 25mL CHCl3.
Combined organic layers were dried over Na2SO4 and filtered. The
filtered organic layers were evaporated under vacuum, and the crude
product was purified on a silica gel flash chromatography column (n-
hexane:EtOAc; 4:1) to afford 3 (60mg lyophilized white-off powder,
49% yield).
2.1.6. Compound 4
(Cycloastragenol-3,6-diacetate) ((20R,24S)-3β,6α,16β,25-tetra-
hydroxy-20,24-epoxy-9,19-cyclolanostane-3,6-diacetate): 200 µL acetic
anhydride (2.112mmol) was added dropwise to a solution of CA
(100mg, 0.203mmol) and 5mg DMAP (0.04mmol) in pyridine
(10.0 mL). The reaction mixture was heated under reflux for 12 h. The
solution of completed reaction mixture was added to the cold 1M HCl
solution (100mL), and it was extracted four times with 25mL CHCl3.
Combined organic layers were dried over Na2SO4 and filtered. The
filtered organic layers were evaporated under vacuum and the crude
product was purified on a silica gel flash chromatography column (n-
hexane:EtOAc; 7:3) to afford 4 (50mg lyophilized white-off powder,
48% yield) [22].
2.1.7. Compound 5
(Cycloastragenol-6-acetate) ((20R,24S)-3β,6α,16β,25-tetrahydroxy-
20,24-epoxy-9,19-cyclolanostane-6-acetate): 100 µL acetic anhydride
(2.112mmol) was added dropwise to a solution of CA (100mg,
0.203mmol) and 5mg DMAP (0.04mmol) in pyridine (10.0mL). The
reaction mixture was heated under reflux for 12 h. The solution of
completed reaction mixture was added to the cold 1M HCl solution
(100mL), and it was extracted four times with 25mL chloroform.
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Combined organic layers were dried over Na2SO4 and filtered. The
filtered organic layers were evaporated under vacuum and the crude
product was purified on a silica gel flash chromatography column (n-
hexane:EtOAc; 5:5) to afford 5 (24mg lyophilized white-off powder,
23% yield) [23].
2.2. Cell culture and treatments
The LNCaP, PC3, RWPE-1 and RAW264.7 cells were obtained from
American Type Culture Collection (ATCC Manassas, VA). LNCaP and
RAW264.7 cells were propagated using RPMI 1640 supplemented with
10% FBS, L-glutamine (2mM), penicillin (100 U/mL) and streptomycin
(100 µg/mL), and PC3 cells were propagated using DMEM F-12 sup-
plemented with 5% FBS, L-glutamine (2mM), penicillin (100 U/mL)
and streptomycin (100 µg/mL) while RWPE-1 cells were propagated in
Keratinocyte growth medium supplemented with bovine pituitary ex-
tract and 5 µM EGF at 37 °C with 5% CO2. FBS used for RAW264.7 cells
were inactivated for 1 h with usual conditions of serum inactivation.
BAY11-7082 (Sigma-Aldrich), celocoxib (Sigma-Aldrich), lipopoly-
saccharide (Sigma-Aldrich), and recombinant TNF-α (Roche) were used
at the recommended concentrations according to the literature.
Molecules were dissolved in DMSO and treatments were done as DMSO
volume will not exceed 0.5% of the culture media volume. Control cells
were treated with the same volume of DMSO used during the molecule
treatments. IC50 concentrations of the molecules were calculated
through nonlinear regression analysis of Graphpad Prism 6. IC10 and
IC20 concentrations were calculated by using the following formula
where ECF is the interested inhibitory concentration, F is the interested
cell viability percent and H is the hill slope: ECF= [F/(100− F)]1/H
*EC50
2.3. Conditioned media (CM) collection and measurement of cytokines in
CM
The U937 monocyte cell line was cultured in RPMI 1640 medium
with 10% FBS (fetal bovine serum) at 37 °C with 5% CO2. To achieve
macrophage differentiation and cytokine production, cells (8× 106)
were grown in 75 cm2 culture flasks for 2 h prior to treatment. Next,
phorbol 12-myristate-13-acetate (PMA) was added at a final con-
centration of 16 nM for 16 h, and adherent clusters were followed. Cells
were washed twice, and 20mL of fresh medium was then added. After
allowing the cells to rest for 2–3 h, lipopolysaccharide (LPS) was added
(10 ng/mL), and the cells were incubated for 24 h. Finally, the super-
natant (conditioned medium – CM) was collected and filtered (0.2 µm)
for further use.
Before feeding the LNCaP cells with CM, TNF-α (Invitrogen), in-
terleukin-6 (IL-6) and interleukin-1beta (IL-1) (Boster Biological
Technology Co., US) levels were assessed by ELISA according to the
manufacturer’s recommendations. Finally, CM with known concentra-
tions of TNF-α was used to induce inflammatory microenvironment in
cell culture [24].
2.4. Antibodies
The antibodies were purchased from the manufacturers as follows:
the NFκB (p65), IκB, p-IκB (S32/36) antibodies were purchased from
Cell Signaling Inc., USA; GAPDH antibody was purchased from Ambion,
US. B-actin antibody was purchased from Sigma-Aldrich; COX1, COX2
and HRP-anti-goat antibodies were purchased from SCBT, Germany.
The HRP-anti-mouse and HRP-anti-rabbit secondary antibodies were
purchased from Amersham, UK and used as recommended.
2.5. WST1 proliferation assay
LNCaP (104) cells were seeded and grown in 96-well plates and
incubated for 48 h. Molecule treatments were performed for 24 h and
WST1 cell proliferation reagent (Roche Cat No: 05015944001) was
used as recommended. Briefly, WST1 (1:10 final dilution) was added
onto the cells at the end of treatments, and the cells were incubated for
an additional 3 h. At the end of the incubation, absorbance measure-
ments at 450 and 690 nm reference wavelengths were performed to
calculate the growth rate.
2.6. NFκB luciferase reporter assay
LNCaP cells (104) were seeded in 96-well culture plates and in-
cubated for 48 h. Cell culture media was replaced with serum/anti-
biotics free culture medium 2 h before the transfection. Negative and
positive control vectors (100 ng/mL), and NFκB (100 ng/mL) reporter
vector (SABiosciences Cignal NFκB reporter luc kit-CCS-013L) were
transfected by Fugene HD transfection reagent (Roche). Normal culture
medium was added onto cells 5 h after transfection, and incubated for a
total 24 h. Treatments were performed for 4 h and cells were collected
with passive lysis buffer according to the recommendations of dual-
luciferase reporter assay kit (Promega, UK). Renilla/firefly luciferase
activity measurements were performed by luminometer (Thermo) ac-
cording to manufacturer’s protocol.
2.7. Nuclear-cytoplasmic fractionation
LNCaP cells (106) were rinsed, scraped into cold PBS and then
centrifuged at 300g for 5min. The pellets were suspended in 250 μL
buffer A (50mM HEPES pH 7.4, 10mM KCl, 1 mM EDTA, 1mM EGTA
with freshly added 1mM DDT, protease and phosphatase inhibitors)
and incubated on a rotator for 30min. Next, the samples were cen-
trifuged at 4000g for 30min, and the supernatant (cytoplasmic extract)
was collected. The cell pellet was washed four times with buffer A and
centrifuged again at 4000g for 5min. After washing, the pellet was
resuspended in 250 μL buffer B (50mM HEPES pH 7.4, 1 mM EDTA,
1mM EGTA, 400mM KCl, and 0.5% Triton X-100 with freshly added
1mM DDT, protease and phosphatase inhibitors) and incubated on a
rotator for 30min. Centrifugation was performed at 14,000g for 30min,
and the supernatant (nuclear extract) was collected. All incubations and
centrifugations were performed at 4 °C.
2.8. Cell lysis, protein extraction and blotting
For protein extraction, cells were grown in 6-cm plates (Sarstedt,
Germany) and washed once with PBS prior to cell lysis. Next, 250 μL
ice-cold modified RIPA buffer (10mM Tris Cl (pH 8.0), 1% Triton X-
100, 0.1% SDS, 0.1% Na deoxycholate, 1mM EDTA, 1mM EGTA and
140mM NaCl) containing both protease and phosphatase inhibitors was
added to the plates, and the cells were then collected into eppendorf
tubes using a cell scraper. The lysates were sonicated for 20 s (25%
power, 0.5 cycles), centrifuged at 12000g for 10min at 4 °C, and the
cleared supernatants were transferred into new tubes. The protein
concentration was determined using a BCA assay (Sigma, UK). Western
blots were performed under standard conditions using 50 μg of protein
lysate per lane. First, the proteins were separated on a 10–12% SDS-
PAGE gel, and transferred to a PVDF membrane (Amersham, UK) using
a wet transfer blotter. The PVDF membrane was blocked with 5% dry
milk in TBS-T (Tris-Borate-Saline solution containing 0.1% Tween 20),
and then primary and secondary antibody incubations were performed
using TBS-T containing 0.5% dry milk or 5% BSA at RT for 1 h or at 4 °C
overnight. The membranes were developed using ECL plus reagent
(Amersham, UK) for 5min, and were photographed using Kodak X-Ray
films in a dark room.
2.9. Total RNA isolation and cDNA preparation
Total RNA was isolated from cultured LNCaP cells using RNeasy kit
(Qiagen, CA). The yield was calculated by using absorbance readings at
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260/280 nm. Additionally, cDNA synthesis was performed using
Superscript III cDNA kit (Invitrogen) according to the recommendations
of the manufacturers.
2.10. Quantitative real time PCR
To examine the gene expression level, quantitative RT-PCR was
performed using a SYBR Green PCR kit and the LC480 PCR system
(Roche, Germany). The relative abundance of each transcript was cal-
culated using the comparative cycle of threshold (CT) method with
GAPDH as an invariant control. The primers utilized are given in
Table 1.
2.11. Measurement of PGE2 level
RAW264.7 macrophages (4×104) were seeded to 96-well plate and
incubated for 24 h. Molecule treatments were performed and cell cul-
ture media was collected for further use in PGE2 Elisa kit (Cayman
Chemicals). PGE2 concentration in supernatant was measured as pg/mL
as recommended.
2.12. Real-time cell proliferation assay
The Xcelligence proliferation assay platform was used for real-time
measurements. Briefly, the LNCaP cells (1x104) were seeded into 96-
well plates (E-plates, Roche GmbH, Germany) and the treatments were
performed. Proliferation rate were monitored by impedance values
collected every 15min for 48 h.
2.13. Statistics
Data are presented as means ± standard deviation (SD). The
Student’s t test with two-tailed equal variance was applied to assess the
statistical significance between pairs when necessary. P < 0.05 was
accepted as significant.
3. Results
In order to find a potent anti-inflammatory molecule that can be a
candidate for chemoprevention of inflammation-induced prostate
cancer, a compound library was prepared from astragenol and cy-
cloastragenol by semi-synthesis studies. A number of analogs, prepared
mainly by acylation and oxidation reactions, and structurally eluci-
dated by spectral methods (1H, 13C NMR and HR-MS; data is shown in
the Supplementary part), were screened for cytotoxicity by WST1 and
for NFκB inhibition activity by luciferase reporter assay on LNCaP
prostate cancer cells (data not shown). The most potent five molecules,
two of which were new (2 and 3), were selected for further studies
(1–5). The structures and syntheses routes are shown in Fig. 1. To
characterize the anti-inflammatory activity of the selected molecules,
NFκB inhibitory activity and molecular mechanisms of the inhibition
experiments were performed.
3.1. Structure elucidation of the new compounds (2 and 3)
Compound 2a was obtained from an oxidation reaction of AG. At
0 °C, Jones oxidation resulted in 2a in 64% yield as previously de-
scribed [21].
Treatment of 2a with sodium methoxide in THF provided com-
pound 2. The HRESIMS data of 2 displayed no mass change (m/z
467.3280 [M+Na]+) compared to the starting molecule 2a. The NMR
spectra of 2a and 2 were almost identical except for the tetrahydrofuran
ring (20,24-epoxy side chain). Detailed inspection of the spectral data
(1- and 2D NMR) revealed that 2 was formed through rearrangement of
the side chain. In the 13C-NMR spectrum, the characteristic signals of C-
20 and C-24 are supposed to resonate ca. at δ 88.0 and 82.5, respec-
tively for CG, AG and 2a possessing 20R,24S absolute stereochemistry
[20,21]. When 13C-NMR and HMQC spectra of 2 were examined to-
gether, an oxymethine carbon was located at δ 82.5, whereas a qua-
ternary carbon resonated at δ 84.5. These two carbon resonances were
assigned unambiguously to C-20 and C-24, respectively. These data
implied stereochemical alteration at C-20 position as S, in accordance
with literature data of related natural products [25,26]. Such a semi-
synthetic rearrangement reaction in cycloartane (9,19-cyclolanostane)
chemistry is being reported for the first time. A plausible mechanism for
the transformation of 2a into the compound 2 was illustrated in Fig. 9.
Compound 3 was obtained from an esterification reaction of CA
using propionic anhydride and DMAP in pyridine. ESI-MS spectrum
showing a major ion peak at m/z 625.3 ([M+Na]+) indicated a mo-
lecular formula of C36H58O7. In the 1H NMR, the characteristic signals
belonging to H-3 and H-6 were shifted to the downfield implying acy-
lation positions. Also, two new methyl signals observed in the upfield
region were assigned to the propionyl groups’ terminal methyl groups.
In addition, in the 13C NMR spectrum, two carbons at 174.3 and 173.8
were readily attributed to the ester carbonyls. Thus, the structure of 3
was established as ((20R,24S)-3β,6α,16β,25-tetrahydroxy-20,24-
epoxy-9,19-cyclolanostane-3,6-dipropionate.
3.2. Cytotoxic activity on LNCaP prostate cancer cells
Cytotoxic activity of the compounds on LNCaP prostate cancer cells
was determined by WST1. Treatments were performed at 100 μM,
50 μM, 25 μM, 12.5 μM, and 6.25 μM concentrations of the molecules
dissolved in DMSO for 24 h. Control cells were treated with the same
volume of DMSO as vehicle. Relative cell viability results were calcu-
lated through normalization of treated cells to control cells.
Cytotoxic activities of the semi-synthetic molecules 1 and 2 were
found to be higher than the starting compound AG (Fig. 2A), and IC50
values were calculated as 20 μM and 82 μM, respectively (Fig. 2B). In
addition, CA analogs showed cytotoxic effects with IC50 values of 14 μM
for 3, 23 μM for 4, and 49 μM for 5 (Fig. 3A). IC50 values were calcu-
lated by Graphpad Prism and IC20 values were derived from IC50 as
explained in methods section for further studies (Figs. 2B and 3B).
3.3. Inhibition of NFκB activity
Since NFκB signaling pathway is suggested as a link between in-
flammation and tumorigenesis, inhibition of NFκB activity is a key
therapeutic strategy to inhibit inflammation-induced carcinogenic me-
chanisms. To investigate NFκB inhibitory activity of the molecules on
LNCaP cells, cells were transfected with NFκB luciferase reporter and
control vectors for 24 h. IC20 concentrations of the molecules and ve-
hicle control were added onto cells w/wo 25 ng/ml TNF-α for 4 h. NFκB
activity was measured for each well and relative luciferase activity was
determined by normalization of % activity of TNF-α-induced cells to
non-induced cells. When NFκB activity was induced to 179 fold by TNF-
α treatment, molecules at indicated concentrations suppressed the ac-
tivity to 98 (AG), 9.8 (1), and 55 (2) fold (Fig. 4A). Cycloastragenol and
its derivatives led to a decrease to 42 (CA), 92 (3), 1.1 (4), and 4.7 (5)
Table 1
Primer pairs used for qRT-PCR amplification.
TNFa Forward GAGGCCAAGCCCTGGTATG
Reverse CGGGCCGATTGATCTCAGC
COX2 Forward CCCTTGGGTGTCAAAGGTAA
Reverse GCCCTCGCTTATGATCTGTC
ICAM1 Forward AGGGTAAGGTTCTTGCCCAC
Reverse TGATGGGCAGTCAACAGCTA
GAPDH Forward CATTGCCCTCAACGACCACTTT
Reverse GGTGGTCCAGGGGTCTTACTCC
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fold (Fig. 5A). Besides, specific NFκB inhibitor BAY11-7082 (5 μg/ml)
was used as a positive control with the suppression activity up to 98
fold.
We subsequently aimed to characterize the inhibition mechanism of
the molecules via inducing cells by either recombinant TNF-α as an
NFκB inducer or conditioned inflammatory microenvironment medium.
In vitro inflammatory microenvironment model was previously devel-
oped and used in our laboratory to simulate prostatic inflammation-
Fig. 1. Structures and preparation of 1–5 from CA and AG.
Fig. 2. A. Viability of LNCaP cells (104) was determined by WST1 method after treatment with increasing concentrations of the molecules (6.25 μM, 12.5 μM, 25 μM,
50 μM, 100 μM) for 24 h. Relative cell viability was calculated through normalization of % cell viability at each concentration to untreated cells. Error bars represent
the standart deviation of 3 replicates at each data point, p < 0,01; B. IC50 concentrations of the molecules, and IC20 concentrations calculated through derivation
from IC50 values of each molecule.
B. Debeleç-Bütüner et al. Steroids 135 (2018) 9–20
13
induced tumor microenvironment in cell culture. Briefly, U937 mono-
cytes are treated with PMA for differentiation to macrophages. Then,
macrophages are stimulated with lipopolysaccharide to induce pro-in-
flammatory cytokine release. Lastly, this conditioned medium (CM) is
collected, filtered and subjected to the measurement of cytokine levels
in order to feed cancer cells by using CM with known cytokine con-
centrations. The levels of TNF-α, IL1β and IL6 are determined by Elisa.
In addition, differently from generally used conditioned media appli-
cations, after the cytokine concentration in CM is measured, CM is di-
luted with normal culture media to adjust the interested concentration
of the cytokine at final inflammatory culture media as effect of TNF-α
has been known to be in an opposite way from each other at relatively
low and high concentrations [2,24].
High levels lead to cell death, whereas moderate levels result in
activation of tumorigenic mechanisms. Therefore, to simulate the
moderate levels of TNF-α as it occurs during chronic inflammation,
concentration of TNF-α in CM is adjusted to appropriate levels ac-
cording to the concept of the experiment as well as previous studies
[24,27]. In this study, we also used this model to investigate the effects
of the molecules against NFκB activation by inflammatory micro-
environment as a supporting method of NFκB activation by re-
combinant cytokine.
When NFκB signaling pathway is stimulated, p65 subunit, which is
present in a cytoplasmic protein complex with IκB, releases from the
complex and translocates to nucleus in order to activate its transcrip-
tional targets. Since its known that some of the specific NFκB inhibitors
show their activity by preventing the translocation of free NFκB p65
subunit to nucleus after it released from the complex, this point of the
signaling cascade has been checked. For this, subcellular fractionation
was performed after LNCaP cells were treated with 40 ng/ml re-
combinant TNF-α for 4 h and nuclear/cytoplasmic NFκB p65 levels
were detected by immunoblotting. Nuclear p65 level was shown to
increase with TNF-α induction and partially reduce by 1 and 2.
Complete inhibition of the translocation BAY11-7082 was also shown
as a positive control (Fig. 4B).
In addition, NFκB can also show their effects by inhibition of any
member of the signaling pathway [4]. To figure out the NFκB inhibition
mechanism of the molecules, changes in protein levels and post-trans-
lational modifications of the NFκB pathway members were in-
vestigated. Since IκBα is localized in the cytoplasm as bound to NFκB
and its phosphorylation as well as proteasomal degradation is induced
due to the activation of NFκB pathway, and the degradation status and
S32/36 phosphorylation of IκB was studied by either TNF-α induction
or inflammatory conditioned media treatment in LNCaP cells. After
Fig. 3. A. Viability of LNCaP cells (104) was determined by WST1 method after treatment with increasing concentrations of molecules (6.25 μM, 12.5 μM, 25 μM,
50 μM, 100 μM) for 24 h. Relative cell viability was calculated through normalization of % cell viability at each concentration to untreated cells. Error bars represent
the standard deviation of 3 replicates at each data point, p < 0,01; B. IC50 concentrations of the molecules and IC20 concentrations calculated through derivation
from IC50 values of each molecule.
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cells were treated with TNF-α for 4 h, TNF-α-induced IκB degradation
detected to be partially suppressed by 1 and 2 where the protein level of
NFκB p65 unit remained unchanged (Fig. 4C). Further, to simulate the
inflammatory microenvironment of the cell in vitro, inflammatory CM
including 125 pg/ml TNF-α was applied onto cells w/wo molecules for
24 h. IκB(S32/36) level was observed to be enhanced by the CM treatment
and decreased with increasing concentrations of the same molecules.
However, NFκB protein level was observed to decrease due to the
treatments possibly related to the cytotoxic effect of the molecules on
cell proliferation (Fig. 4D). COX2 alteration in protein level was also
checked in inflammatory microenvironment and its increased protein
level after CM was repressed by 1 and 2, while no change was seen at
COX1 level (Fig. 4E).
In addition, cycloastragenol derivatives were also investigated at
the same experiment settings and decrease of nuclear NFκB p65 level
was also determined in the presence of 3, 4, and 5 (Fig. 5B). Further,
TNF-α-induced IκB degradation was recovered by 3, but not by 4 and 5.
NFκB levels remained the same in the presence of 3, however decreased
by 4 and 5. Therefore, it is suggested that 4 and 5 not only repress NFκB
signaling at these concentrations but also show further inhibitory effect
on cell viability and still have a severe cytotoxic effect on cell survival
(Fig. 5C). Further, in inflammatory microenvironment, induced IκB(S32/
36) level was repressed partially by 3 and totally to the basal level by 4
and 5 (Fig. 5D). In addition, COX2 expression was repressed by all cy-
cloastragenol derivatives without COX1 inhibition (Fig. 5E).
3.4. Inhibition of NFκB transcriptional activity
In order to check the ultimate effects of NFκB inhibition at tran-
scriptional level, relative mRNA levels of NFκB transcriptional targets
were determined by qRT-PCR after LNCaP cells were treated with the
indicated concentrations of the molecules w/wo 25 ng/ml TNF-α for
4 h. Key transcriptional targets of NFκB, which are among important
mediators of inflammation-induced carcinogenesis, were investigated.
Relative mRNA level of tumor necrosis factor-α (TNF-α), which is one
of the major mediators of inflammation was detected to be induced to
78 fold due to TNF-α treatment. The highest suppression was seen in 5
treatment as 46 fold while inhibition by BAY11-7082 at its NFκB in-
hibitory concentration was 53 fold. Relative mRNA levels due to other
molecules were determined as 1 (56 fold), 2 (49 fold), 3 (57 fold), 4 (54
fold), 5 (46 fold). Another transcriptional target, cyclooxygenase-2
(COX2) that activates antiapoptotic, angiogenic, and metastatic
Fig. 4. A. Inhibitory effects of the molecules on NFκB signaling pathway in LNCaP cells were determined by NFκB luciferase reporter assay. 104 LNCaP cells were
transfected with NFκB luciferase reporter vector and incubated for 48 h. AG (100 μM), 1 (15 μM) and 2 (50 μM) were added onto cells w/wo recombinant TNF-α
induction (40 ng/ml) for 4 h. Dual luciferase activity was measured and relative luciferase activity was calculated as fold change of luciferase activity of TNF-α
treated cells versus untreated cells after firefly/renilla normalization. Blue bars represent TNF-α untreated and red bars represent TNF treated cells. Error bars
represent the standard deviation of 3 replicates, p < 0,001; B. LNCaP cells (7,5×105) were treated with recombinant TNF-α (40 ng/ml) w/wo 1 (15 μM) and 2
(50 μM) and BAY11-7082 (5 μg/ml) for 4 h. Cytoplasmic and nuclear fractions were isolated and subcellular protein levels of NFκB p65 and IκB were determined by
western blot. GAPDH blotting and polyacrylamide gel staining (not shown) were used as loading control. BAY11-7082 treatment was performed as a positive control
of NFκB specific inhibition; C and D. Effects of the molecules on NFκB pathway proteins were determined by western blot after the treatment of 4×105 LNCaP cells
with (C) TNF-α (40 ng/ml) w/wo 1 (15 μM) and 2 (50 μM) for 4 h and (D) conditioned media (CM) including 125 pg/ml TNF-α w/wo 1 (IC10:4 μM, IC20:15 μM,) and
2 (IC10:14 μM, IC20:50 μM) of the molecules for 24 h; E. Inhibition of COX1 and COX2 proteins were determined after treatment with conditioned media (CM)
including 125 pg/ml TNF-α w/wo 1 (15 μM) and 2 (50 μM) for 24 h. B-actin and GAPDH were used as loading controls.
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pathways was induced to 12 fold by TNF-α treatment and suppressed to
6 fold by the molecules 1, 4 and 5, whereas 2 and 3 caused 7 and 8 fold
suppression, respectively (Bay11-7082: 8 fold). In addition, inter-
cellular adhesion molecule-1 (ICAM1) functioning in migration and
invasion of tumor cells was determined to increase 41 fold by TNF-α,
and suppressed by the compounds (5:17 fold; 1: 20 fold; 2: 18 fold; 3:
25 fold; 4: 23 fold; Bay11-7082: 25 fold) (Fig. 6).
3.5. Inhibition effects on PGE2 release
This study mainly focuses on the discovery of chemopreventive
molecules for inhibition of inflammation-induced tumorigenic altera-
tions; therefore, measurement of Prostagladin E2 (PGE2) is also taken
into consideration as it has a driving role in tumorigenic alterations
during inflammation. Inhibition of PGE2 release by the compounds was
investigated in RAW264.7 macrophages. Cells were seeded in 96-well
plates with 4× 104/well confluence and incubated for 24 h. Then in-
dicated concentrations of the molecules were applied onto cells with
1 μg/ml LPS concurrently for 24 h and PGE2 levels were measured in
culture media by Elisa. Basal level of PGE2 was detected as 7 pg/ml in
cell culture media and induced to 17.5 pg/ml by LPS with a subsequent
suppression up to 12 pg/ml by selected compounds. Selective COX2
inhibitor celecoxib was found to suppress the PGE2 level to 9 pg/ml as a
positive control (Fig. 7).
3.6. Inhibition on prostate cancer cell proliferation
In order to observe the ultimate effect of NFκB inhibitory activity of
the molecules on cell proliferation, LNCaP, PC3 and RWPE1 cells were
treated with the NFκB inhibitory concentrations of the molecules, and
subjected to Xcelligence real-time cell proliferation system for 48 h.
Impedance values detected in every 15min for 48 h were graphed. It
was seen that inhibition of NFκB pathway resulted in suppressed cell
proliferation in LNCaP cells as well as PC3s with a lower effect.
However, proliferation of RWPE1 normal prostate epithelial cells has
also been decreased by molecule treatments. Inhibitory effect of CA-
derived molecules 3, 4 and 5 was found to be greater than AG-derived 1
and 2 on all cell lines (Fig. 8).
Fig. 5. A. Inhibition effects of the molecules on NFκB signaling pathway in LNCaP cells were determined by NFκB luciferase reporter assay. 104 LNCaP cells were
transfected with NFκB luciferase reporter vector and incubated for 48 h. CA (100 μM), 3 (5 μM), 4 (20 μM), 5 (30 μM) were added onto cells w/wo recombinant TNF-
α induction (40 ng/ml) for 4 h. Dual luciferase activity was measured and relative luciferase activity was calculated as fold change of luciferase activity of TNF-α
treated cells versus untreated cells after firefly/renilla normalization. Blue bars represent TNF-α untreated and red bars represent TNF-α treated cells. Error bars
represent the standart deviation of 3 replicates, p < 0,001; B. LNCaP cells (7,5× 105) were treated with recombinant TNF-α (40 ng/ml) w/wo 3 (5 μM), 4 (20 μM),
5 (30 μM) and BAY11-7082 (5 μg/ml) for 4 h. Cytoplasmic and nuclear fractions were isolated and subcellular protein levels of NFκB p65 and IκB were determined by
western blot. GAPDH blotting and polyacrylamide gel staining (not shown) were used as loading control. Absence of GAPDH in nuclear fraction was interpreted as
the accuracy of cytoplasmic-nuclear separation. BAY11-7082 treatment was performed as a positive control of NFκB specific inhibition; C and D. Effects of the
molecules on NFκB pathway proteins were determined by western blot after the treatment of 4× 105 LNCaP cells with (C) TNF-α (40 ng/ml) w/wo 3 (5 μM), 4
(20 μM), 5 (30 μM) for 4 h and (D) conditioned media (CM) including 125 pg/ml TNF-α w/wo 3 (IC10:2 μM, IC20:5 μM), 4 (IC10:4 μM, IC20:20 μM) and 5 (IC10:9 μM,
IC20:30 μM) of the molecules for 24 h; E. Inhibition of COX1 and COX2 proteins were determined after treatment with conditioned media (CM) including 125 pg/ml
TNF-α w/wo 3 (IC20:5 μM), 4 (IC20:20 μM) and 5 (IC20:30 μM) for 24 h. B-actin and GAPDH were used as loading controls.
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4. Discussion
Inflammation and subsequent unbalanced anti-inflammatory re-
sponse were known to activate tumorigenic mechanisms. Moreover, use
of anti-inflammatory drugs was shown to reduce the incidence of many
cancer types including colon and prostate by previous studies [28,29].
Therefore, implementation of the right therapy approaches targeting
inhibition of inflammation-induced tumorigenic mechanisms has a key
interference in treatment of inflammatory diseases. In this study, we
aimed to evaluate the potential anti-inflammatory activity of the sa-
pogenol derivatives against prostatic inflammation as a chemo-pre-
ventive strategy for inflammation-induced prostate cancer develop-
ment.
Although cytokine production induced through macrophage in-
filtration in acute inflammatory microenvironment is suppressed by
anti-inflammatory therapy, it is detected that cytokine levels may not
be turned to their basal levels for long periods leading to chronic
inflammation. In addition, moderate levels of TNF-α induce tumori-
genic alterations in contrary to its cellular effects at high levels, which
lead to cell death. This uncontrolled and sustained production of TNF-α
alters cellular mechanisms functioning in proliferation, apoptosis, an-
giogenesis and differentiation [2,7]. Since NFκB has a regulatory role in
all these cellular events, inhibition of NFκB signaling is one of the ef-
ficient ways of preventing inflammation-related carcinogenesis. In this
study, we showed that the semi-synthetic compounds 1–5 were efficient
to prevent NFκB activation stimulated by both recombinant TNF-α and
CM treatment representing inflammatory microenvironment. Interac-
tion of TNF-α with other cytokines in an inflammatory microenviron-
ment also has a significant effect in tumorigenic alterations. Therefore,
we used in vitro inflammatory microenvironment model to ensure that
our molecules are not only effective on TNF-α-induced inflammatory
signaling, but also on general pro-inflammatory mechanisms involved
by other cytokines.
Effects of the compounds on cell viability were assessed with their
NFκB inhibition results during the evaluation of their anti-inflammatory
potentials. Since the NFκB inhibition activity of cycloastragenol-derived
molecules were determined to be higher than astragenol-derived mo-
lecules at relatively lower concentrations, 3, 4 and 5 were suggested to
be promising for treatment of prostatic inflammation and inhibition of
NFκB-related tumorigenic activation in prostate cells. In addition, effect
of 4, which was determined as an increase on LNCaP cell viability at
first two concentrations, suggested that relatively low levels of 4 en-
hances cell proliferation opposing to its effect at high concentrations
alike TNF-α as explained above.
NFκB signaling is modulated by many post-translational modifica-
tions and many natural products show NFκB inhibition activities by
acting on different steps of the signaling cascade. As NFκB has a central
role for a wide range of pathologies including inflammation and cancer,
drug development studies focused on this pathway and more than 700
of NFκB inhibitors have been identified [30]. Activity mechanisms of
many NFκB inhibitors have been characterized and it has been found
that IκB kinases’ (IκKs) inhibition or IκK phosphatases’ activation are
major strategies. In addition, inhibition of IKB proteasomal degradation
such as mechanism of bortezomib, inhibition of NFκB acetylation, and
inhibition of NFκB nuclear accumulation are further mechanisms
identified [31]. In our study, we also showed the inhibition of CM-in-
duced NFκB signaling was achieved by molecules through suppression
Fig. 6. Relative mRNA levels of (A) TNF-α, (B) ICAM1, and (C) COX2 were determined in LNCaPs by qRT-PCR after treatment with TNF-α (40 ng/ml) w/wo the
molecules 1, 2, 3, 4, and 5 for 4 h. The results were analyzed by ΔΔCt method, briefly, fold change of treated sample to control was calculated after normalization of
target gene to GAPDH. BAY11-7082 (5 μg/ml) treatment was performed as a positive control of NFκB inhibition. Error bars represent the standard deviation of 3
replicates, p < 0,001 for molecule treatments with TNF-α vs only TNF-α.
Fig. 7. Inhibition effect of molecules (1:4 μM, 2:50 μM, 3:2 μM, 4:4 μM,
5:30 μM) on PGE2 levels were determined in RAW264.7 macrophage cells
(4× 104/well) by Elisa. Induction of PGE2 release by 1 μg/ml lipopoly-
saccharide (LPS) treatment was performed with simultaneous molecule treat-
ments. PGE2 levels were measured in culture media of the cells after 24 h
treatment. Celecoxib (1 μM) was used as positive control. Error bars represent
the standart deviation of 3 replicates, p < 0,001 for molecule treatments with
LPS vs only LPS.
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of the IκB phosphorylation. Since, inhibition activity was observed to
start at the beginning of the activation cascade, it is suggested that
molecules might show this activity through inhibition of IκK kinases
and can also interact with IκKs that are responsible from IκB S32/36
phosphorylation [32,33].
The molecules were also detected to decrease the relative mRNA
level of COX2, so decrease in PGE2 release is suggested to result from
the inhibition of transcriptional activity of NFκB pathway by the mo-
lecules and not from a direct inhibition on COX2 activity. Further,
adverse effects of non-selective COX inhibitors on gastrointestinal
system are known as a limiting factor for anti-inflammatory therapy.
Protein levels of COX2 in an inflammatory microenvironment were
suppressed by 1, 3, 4 and 5 without COX1 inhibition, which can be an
advantage for the use of these molecules as an anti-inflammatory agent
with an overall inhibition of tumorigenic mechanisms without side ef-
fects of non-selective COX inhibitors [34].
Increase in prostate cancer incidence was ascribed to the western
lifestyle in developed countries. Therefore, chemoprevention with
dietary agents or plant-derived phytochemicals instead of toxic che-
motherapy could be a successful approach in prostate cancer manage-
ment [29]. Because of the key role of NFκB inhibition for preventing
inflammation-related prostate cancer tumorigenesis, many natural
products screened for this biological activity. Silibinin and genistein,
which are polyphenolic flavonoids and lycopene, which is a carotenoid,
have been also reported to target NFκB pathway and promising mole-
cules for prostate cancer inhibition [29]. Curcumin is another natural
molecule in phase II clinical trial for pancreatic cancer [35]. Supporting
our data, triterpenoid saponins have also been shown to be efficient on
Fig. 8. Inhibition effects of the molecules on proliferation of (A) RWPE1, (B) LNCaP, and (C) PC3 cells at NFκB inhibitory concentrations (1:15 μM, 2: 50 μM, 3: 5 μM,
4: 20 μM, 5: 30 μM) were determined by Xcelligence real time cell analysis system. Standard deviation of 5 replicates was calculated at each data point (not shown),
p < 0,001.
Fig. 9. A plausible mechanism for the synthesis of compound 2.
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NFκB inhibition previously [36]. The synthetic triterpenoid 2-cyano-3,
12-dioxooleana-1, 9(11)-dien-28-oate (CDDO) was derived from olea-
nolic acid, and its inhibitory effect on NFκB signaling was shown with
ultimate anti-inflammatory and antitumoral activities proving the
therapeutic potential [37,38]. Furthermore, inhibitory activity of CDDO
on NFκB and tumor formation has been also determined in mouse
model of prostate cancer [39].
Most of the drugs approved by FDA are either directly used mole-
cules or modified compounds from plants. Furthermore, more than 60%
of antitumor and anti-infectious drugs already in market or in clinical
trials are from natural sources [29]. Since Astragalus saponins have also
been reported to have anticarcinogenic effects [40], it has been sug-
gested that astragenol- and cycloastragenol-derived molecules in this
study are promising anti-inflammatory agents for prostate cancer che-
moprevention and should be further characterized for the possible in-
hibitory effects on other inflammation-related tumorigenic pathways.
In addition, we would like to draw attention to protein acylation,
which is a key post-translational modification in cellular systems. The
acyl groups can differ in structure from modified long chain fatty acids
to the smallest unit, acetate, all of which can be activated and cova-
lently attached to diverse amino acid side chains such as lysine, cy-
steine, serine, threonine and N-terminal. Subsequently this covalent
modification modulates protein’s function. For example, acetylation of
lysine residues can change the charge state of proteins leading to new
recognition elements for protein–protein interactions. On the other
hand, long chain fatty-acylation enables spatial control of cell signaling
by targeting proteins to membranes [41]. A few studies report that
possessing acyl groups on saponin framework is important for cyto-
toxicity [42,43]. Recently, acetyl salicylic acid (Aspirin) extensively
used for its anti-inflammatory, antipyretic, analgesic and anti-throm-
botic effects, has been shown to decrease the incidence of cancers of
epithelial origin. Studies over the past decades suggest that, besides
cyclooxygenases, aspirin acetylates other cellular proteins. Researchers
also postulate aspirin’s possible acetylation targets as RNA, and meta-
bolites such as CoA, causing a change in their function [44].
From structure activity relationship and mechanism of action per-
spectives, the following should be taken into consideration. During our
screening studies of semi-synthetic cycloartane derivatives, it was rea-
lized that acylation of the saponin framework from one or two positions
(mainly C-3 and C-6 secondary alcohols) resulted in higher cytotoxicity.
Complete activity loss in tri- and tetra-acylated analogs made clear that
polarity change towards non-polar compounds was not the overriding
basis for the toxicity on cancer cell lines (data not shown). Keeping the
recent protein acylation reports in mind, as 1, 3, 4 and 5 are all acylated
analogs, we speculate that these compounds may show their activities
via acetylating (in the case of 1, 4 and 5) or propionylating (in the case
of 3) protein targets, both of which are post translational modifications
occurring in cellular systems. Therefore, for our bioactive acylated
compounds, further studies are warranted firstly focusing on acylation
hypothesis at global protein level, followed by identifying specific anti-
inflammatory or novel acylation targets.
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